Anil Koul

Anil Koul
Born (1972-06-01) 1 June 1972
India
Alma materMax-Planck Institute for Biochemistry (MPI), Munich Germany & CSIR-IGIB Delhi and Delhi University, India
AwardsAmerican Chemical Society (ACS) - Heroes of Chemistry Award (2020); Sun Pharma Research Award (2017); Johnson Medal (2013); Swiss-TB prize (2005)
Scientific career
InstitutionsInstitute of Microbial Technology, Chandigarh 160036, India. LSHTM, London, UK.

Anil Koul (born 1 June 1972) is a scientist and former Director of India's CSIR-Institute of Microbial Technology (IMTECH).[1] He is also the vice president and Head of Global Public Health discovery at Johnson & Johnson. He is member of Board of Directors of Janssen Pharmaceutica NV, the European subsidiary of J&J. He is also a professor of Translational Discovery at London School of Hygiene and Tropical Medicine (LSHTM).[2]

His major scientific career achievement is his key role in the discovery and development of a new tuberculosis drug, bedaquiline, the first drug approved in 45 years for treatment of drug-resistant tuberculosis. Koul has been awarded a number of awards for his contribution to discovery of Bedaquiline.

Early life and education

Koul was born in Srinagar, Kashmir and completed his secondary school education in Srinagar till 1990 and further bachelor's and master's degrees from Delhi University. Koul obtained his PhD at Delhi University and at Max-Planck Institute (MPI) of Biochemistry in Germany in 2001.

Career

Koul's initial research focused on kinase and phosphatase in the laboratory of Axel Ullrich[3] at MPI and subsequently in Axxima Pharmaceuticals, a biotech company in Munich. In 2004, Koul joined the US multinational Johnson & Johnson, He worked as senior director and headed its respiratory infections discovery unit based in Europe and US. In late 2016, Anil moved to India to run the CSIR-IMTECH in Chandigarh.[4]

Scientific contributions

Koul's key achievement has been as one of the core scientist at J&J involved in discovery of multi drug-resistant tuberculosis drug Bedaquiline.[5] Bedaquiline has been conditionally approved in US, Europe and several high TB burden countries like India, China and South Africa. In 2013, the World Health Organization (WHO) put bedaquiline on list of its essential medicines.[6] Bedaquiline received a prestigious Prix Galien Award for most innovative Orphan Drug (UK) in 2016.[7] In 2019, India's Health Ministry made bedaquiline available across more than 500 drug-resistant TB centers in India[8] to help India's End TB program.[9] To date, bedaquiline has been approved for use in more than 60 countries and is part of national TB eradication plans across the world.[10] In 2020, US FDA approved new pediatric formulation of Bedaquiline (>=5 years).[11]

Koul has extensive scientific contributions to drug discovery and translational research. Koul and his team have discovered more than 3 other drug candidates, two of which are into late stage human testing including one for serious respiratory viral infections (RSV).[12] Koul has several publications in leading journals like Nature and Science and more than 25 international patents to his credit.

As Director IMTECH, he oversaw R&D and non R&D staff of more than 350 people and was responsible for scientific strategy, finance, general administration, business development, procurement, communication & public relations. At IMTECH, Koul played a pivotal role in establishing new research divisions like medicinal chemistry, and virology centers.[13] He established several industry-academia partnerships like Zydus Cadila and a high end skill development centre in partnership with MERCK.[14] In 2018, IMTECH's Bioinformatics Unit was among top institutions in world in number of biological databases.[15] Koul made policy changes including 'ease of doing science' and a new centralized admin block.

Koul has played key roles in several high level government committees.

Awards and honors

In 2020, American Chemical Society awarded Koul along with two of his colleagues the Heroes of Chemistry Award[16][17] for the discovery of bedaquiline.

In 2017, Koul was conferred with 'Sun Pharma Science Foundation Award'[18][19] by India's Health Minister for his contribution to discovery of bedaquiline. He was also awarded with the 'Swiss-TB Award' (2005) by the Swiss Foundation for Pneumology Research[20] and Johnson Medal (2013).

He has featured in Voice of America's (VOI) radio news analysis[21] and India's electronic news channels (NDTV) 'Every Life Counts Program'.[22]

Board membership

Koul has served on a number of corporate boards, including.

  • Scientific Advisory Board Member, CSIR.[23]
  • Research Council Member of CSIR-Central Drug Research Institute, Lucknow.[24]
  • Board of Directors, Technology Business Incubator, Kalinga Institute of Industrial Technology, Bhubaneswar.[25]
  • Member of Board of Directors, Janssen Pharmaceuticals NV, Belgium.

References

  1. ^ Kanwar, Shimona (13 August 2016). "From Belgium to city for Imtech". The Times of India. Retrieved 14 June 2018.
  2. ^ "LSHTM". LSHTM.
  3. ^ Laboratory of Alex Ullrich (http://www.biochem.mpg.de/en/rd/ullrich Archived 7 June 2017 at the Wayback Machine)
  4. ^ "J&J scientist helping fight tropical diseases in India". 7 June 2017.
  5. ^ SIRTURO- MDR-TB Drug (https://www.sirturo.com/)
  6. ^ WHO Conditional Approval SIRTUR https://www.jnj.com/media-center/press-releases/sirturo-bedaquiline-receives-conditional-approval-in-the-european-union-for-the-treatment-of-multi-drug-resistant-tuberculosis
  7. ^ "Winners – Galien Foundation". Retrieved 11 June 2019.
  8. ^ Health, Ministry of (6 January 2019). "For Drug-Resistant TB (DR-TB) patients, a better and newer drug regimen Bedaquiline is now available across 428 district level DR-TB centres and 148 specialized DR-TB centres. #SwasthaBharat #TB #Tuberculosis #EndTBpic.twitter.com/GWAYSwkwq5". @mohfw_india. Retrieved 11 June 2019.
  9. ^ "National Strategic Plan for Tuberculosis Elimination 2017–2025" (PDF). tbcindia.gov.in. March 2017. Retrieved 26 November 2020.
  10. ^ "TBFacts".
  11. ^ "Drugs History - Sirturo".
  12. ^ "Clinical Trials". 24 June 2021.
  13. ^ ""IMTECH's translational science agenda holds a big promise"". 13 June 2019.
  14. ^ "CSIR to establish a High-End Skill Development Centre in Chandigarh". pib.nic.in. Retrieved 20 April 2019.
  15. ^ "Statistics - Database Commons". bigd.big.ac.cn. Retrieved 20 April 2019.
  16. ^ "ACS Heroes of Chemistry".
  17. ^ "American Chemical Society - Janssen J&J - 2020 Heroes of Chemistry". YouTube. 3 November 2020.
  18. ^ The Tribune (http://epaper.tribuneindia.com/1188387/ChandigarhTribune/CT_29_April_2017#page/2/1)
  19. ^ Sun Pharma Science Foundation award- (http://www.sunpharma.com/responsibility/csr/ranbaxy-science-foundation Archived 9 June 2017 at the Wayback Machine)
  20. ^ "2005 SwissTB Award: Drs. Liem Nguyen, Anne Walburger, Giorgio Ferrari, Anil Koul". www.swisstb.org. Retrieved 16 December 2018.
  21. ^ Voice of America’s radio news https://www.voanews.com/a/little-progress-made-against-tuberculosis---114800769/171357.html
  22. ^ India’s NDTV every life counts program https://www.youtube.com/watch?v=hDW5-2S4VkM
  23. ^ "CSIR" (PDF).
  24. ^ "Research Council" (PDF). www.cdri.res.in. 16 January 2019. Archived from the original (PDF) on 16 December 2018. Retrieved 16 December 2018.
  25. ^ "KIIT | Kalinga Institute of Industrial Technology Bhubaneswar". KIIT. Retrieved 16 December 2018.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.